# openevidence - PE Due Diligence Dashboard

**Generated**: 2025-11-21 11:45:11 UTC

---

## 1. Company Overview
OpenEvidence is positioned as a leading medical information platform, launched from the Mayo Clinic Platform Accelerate program. The company aims to address the challenge of information overload in the medical field by organizing and expanding the world's collective medical knowledge. The platform features multimedia and clinical findings sourced from reputable publications such as The New England Journal of Medicine and JAMA.

While specific details regarding the founding year and headquarters location are not disclosed, the company operates within the medical information category, targeting healthcare professionals in the U.S. The mission of OpenEvidence reflects a commitment to enhancing the accessibility and usability of medical information for practitioners, thereby improving patient outcomes.

## 2. Business Model and GTM
OpenEvidence operates a B2B business model, primarily targeting U.S. healthcare professionals. The platform is offered free of charge to verified healthcare providers, which allows for broad accessibility and engagement within the medical community. The go-to-market strategy focuses on leveraging partnerships with established medical institutions and publications to enhance credibility and attract users.

The competitive positioning of OpenEvidence is strengthened by its unique content offerings and the backing of renowned institutions like the Mayo Clinic. However, specific details regarding pricing strategy beyond the free access model, as well as information on direct competitors, remain undisclosed.

## 3. Funding & Investor Profile
As of the latest available data, OpenEvidence has not disclosed any funding raised, with a total of one funding round reported. The details of this round, including the date, amount, and lead investors, are not available. The investor composition includes notable firms such as Thrive, BOND, Sequoia, ICONIQ, Coatue, Kleiner Perkins, Breyer Capital, Mayo Clinic, Greycroft, Blackstone, and Google Ventures, indicating a strong backing from prominent venture capitalists in the healthcare and technology sectors.

Current valuation information is also not disclosed, leaving a gap in understanding the company's financial standing in the market.

## 4. Growth Momentum
Information regarding headcount trends and hiring activity is not disclosed, which limits the assessment of the company's growth momentum. There are no available details on office locations, geographic expansion, partnerships, or recent product launches. Additionally, customer and revenue growth signals are not reported, making it challenging to evaluate the company's trajectory and market penetration effectively.

## 5. Visibility & Market Sentiment
OpenEvidence has received limited visibility, with three news mentions in the past 30 days. The sentiment score related to these mentions is not disclosed, which could provide insights into public perception. The platform has garnered minimal engagement on GitHub, with three stars, and lacks a Glassdoor rating or reviews, indicating a potential area for improvement in employer branding and public relations.

No awards or notable media coverage have been tracked, suggesting that the company may need to enhance its marketing efforts to increase awareness and recognition in the industry.

## 6. Risks and Challenges
Currently, no major risks have been identified in the available data. However, the absence of disclosed operational challenges, competitive threats, or regulatory concerns may indicate a lack of comprehensive risk assessment. The medical information sector is inherently competitive and subject to rapid changes in technology and regulations, which could pose challenges that are not yet apparent.

## 7. Outlook
The outlook for OpenEvidence appears cautiously optimistic, given its mission to improve medical information accessibility. Growth opportunities may arise from expanding partnerships with healthcare institutions and enhancing product offerings to meet the evolving needs of healthcare professionals. Strategic initiatives could include leveraging artificial intelligence and data analytics to further refine the platform's capabilities. However, without detailed metrics and market analysis, the future prospects remain uncertain.

## 8. Disclosure Gaps
Several critical pieces of information were not publicly disclosed, which limits the ability to conduct a thorough analysis. These gaps include:
- Founded year
- Company valuation
- Headcount
- Headcount growth rate
- Customer count
- Revenue

The absence of these metrics raises concerns about the overall transparency of OpenEvidence and its operational status in the competitive landscape.